Key clinical point: Intensive surveillance with carcinoembryonic antigen testing and CT scans after colorectal cancer resection did not improve survival when compared with standard abdominal ultrasound/chest x-ray monitoring in a phase 3 trial.
Major finding: At a median follow-up of 6.5 years, there were no significant differences in 5-year overall survival (P = .340) or recurrence-free survival (P = .473).
Study details: A phase 3 trial of 1,995 patients with stage II/III colorectal cancer who underwent resection with curative intent.
Disclosures: The study is ongoing and being funded by the Federation Francophone de Cancerologie Digestive. Dr. Lepage disclosed ties with Novartis, Amgen, Bayer, Servier, and AAA.
Lepage C et al. ESMO 2020, Abstract 398O.